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Abstract
Background: Chemoprophylaxis for travellers' malaria is problematic. Decision modeling may help determine optimal 
prevention strategies for travellers' malaria. Such models can fully assess effect of drug use and disease on quality of life, 
and help travellers make informed values based decisions. Such models require utility values reflecting societal 
preferences over different health states of relevance. To date, there are no published utility values relating to clinical 
malaria or chemoprophylaxis adverse events.
Methods: Utility estimates for health states related to falciparum malaria, sequelae and drug-related adverse events 
were obtained using a self-administered visual analogue scale in 20 individuals. Utility values for health states related to 
clinical malaria were obtained from a survey of 11 malaria experts questioned about length of hospital stay or 
equivalent disability with simple and severe travellers' malaria.
Results: The general public (potential travellers), were more tolerant of taking prophylaxis if associated with no or mild 
AEs and least tolerant of mild sequelae from malaria and severe drug related events. The rating value reported for 
taking no prophylaxis was quite variable. Tropical medicine specialists estimated a mean hospital stay 3.23 days (range 
0.5-4.5 days) for simple and 6.36 days (range 4.5 - 7 days) for severe malaria.
Conclusions: This study provides a benchmark for important utility value estimates for modeling malaria and drug-
related outcomes in non-immune travellers.
Background
There is little doubt that experiencing clinical malaria or
drug-related adverse events (AEs) with malaria chemo-
prophylaxis will impact an individual's quality of life. Cur-
rently, there is disagreement, and often much heated
debate among travel medicine providers and public
health authorities concerning the benefit of taking
chemoprophylaxis to prevent clinical malaria within cer-
tain areas of risk [1-10]. Those advocating for decreasing
use of chemoprophylaxis cite drug related AE and risk-
benefit assessments.
To best make decisions about the appropriateness of
malaria chemoprophylaxis, it is necessary to construct a
decision-model, which allows a systematic approach to
assessing the trade-off between risks and benefits. Such a
model would require the use of utility values, which
reflect societal preferences over different health states of
relevance. Utility values are measures of a decision
maker's relative preferences for different outcomes asso-
ciated with health care interventions. When using utility
values, analysts place a value of a health outcome assess-
ing the outcome relative to death, which has a score of 0
and perfect health which has a score of 1. By aggregating
utility values weighted by the probability of health out-
comes an aggregate score summarizing the value of an
intervention can be obtained.
However, to date, there are no published utility values
relating to clinical malaria or chemoprophylaxis adverse
events. Such utility values are necessary for the construc-
tion of models that would allow full examination of risks
and benefits, and could consider all possible outcomes
related to malaria and chemoprophylaxis, even severe
adverse outcomes and death. An additional benefit to
such a model would be the ability to simulate outcomes
from hundreds of thousands of travellers to areas with
differing risk of malaria and differing use of chemopro-
phylaxis. Such simulations would provide outcome mea-
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sures for these travellers, including numbers of resulting
malaria cases and deaths with each option, as well as drug
related events. Such information would be of benefit to
policy makers and travel medicine providers advising
travellers about malaria risk and prevention strategies.
Given the lack of available utility values, the objective of
this study was to determine the utility values related to
clinical malaria and drug- related adverse events, which
can be employed in decision models. These estimates
were obtained from two anonymous surveys, carried out,
after ethics approval (London School of Hygiene and
Tropical Medicine and the Ottawa Health Research Eth-
ics Board) and voluntary informed consent.
Methods
Survey of general public (Potential travellers)
There are risks (AEs) and benefits (reduction of clinical
malaria) associated with drugs used to prevent malaria.
Therefore, it is necessary to weigh the risks against the
values of the therapy. Utility estimates for health states
related to non-severe falciparum malaria, sequelae and
drug-related AEs were obtained through a convenience
sample of 20 non-health care employees in an academic
hospital setting (14 females and 6 males) using a self-
administered visual analogue scale (VAS) based on the
scale employed as part of the EQ-5D instrument[11]. The
EQ5D is a generic, quality of life instrument developed to
elicit an overall measure of health status. The EQ-5D
contains both a health status questionnaire and a self-
administered visual analog scale (VAS), which was used
in this analysis. The scale is a standardized, non-disease
specific VAS developed to describe and attach values to a
common core of health states detailing various quality of
life levels. The scale is organized vertically like a ther-
mometer and eight different descriptions of health states
are organized at the periphery of the scale, so that all
states can be considered simultaneously. The scale is gen-
erally anchored with perfect health as the highest possi-
ble value and death or worst imaginable health as the
bottom anchor. The 100-millimetre thermometer ranges
from 0 (dead) to 100 (perfect health) and participants rate
the value of a certain health state by drawing a line from
the description text box to intersect the thermometre.
The resulting value is the number of millimeters from the
zero or "dead", divided by 100. Figure 1 presents the
design of the VAS as well as a description of various sce-
narios related to malaria risk and outcomes, chemopro-
phylaxis and health states that were assigned a value by
each of the respondents.
When a VAS is used to estimate societal preferences, a
power calculation has been suggested as a means to con-
vert the values (v) obtained into utilities (u)[12]. This is
done by using a standard power function relationship
given by: (1-u) = (1-v)α, where α allows incorporation of
the attitude to risk within the population (alpha > 1 repre-
sents risk aversion)[12,13]. A value of alpha of 2.29 was
assumed based on a previous Canadian study[13]. The
alpha was obtained through comparing individuals'
scores from using both a VAS and a standard gamble
exercise - a more complex measure of utility measure-
ment[14]. Thus, if a respondent rated a health state at 50,
the VAS score would be 0.5 (50/100) and the utility value
would be 0.80 (1-(1-0.5)2.29).
Survey of malaria experts
Utility values for clinical malaria health states in travellers
were obtained from a brief questionnaire of 11 tropical
medicine experts (four females and seven males) each
with five or more years of experience treating malaria.
They were questioned about length of hospital stay
(including days in ICU) or equivalent disability related to
simple and severe clinical malaria in a non-immune trav-
eller. Utility values were calculated for a one- week time
of risk. This timeframe was chosen since travellers itiner-
aries vary widely, and having a weekly value may be more
easily applicable within a model that addresses variable
length of travellers malaria risk. As per previous studies,
conservative assumptions were adopted relating to the
utility value associated with the duration of hospitaliza-
tion (LOS) - a utility value of zero during length of
stay[15]. So that a one week utility value (u) is defined as
follows:
u = 1 - (LOS/7). Thus, if a respondent felt that severe
clinical malaria required a five-day hospitalization the
derived utility value was 0.29 (1 - 5/7).
Results
Survey of general public
The results of the malaria and malaria drug VAS and their
respective utility estimates are presented in descending
order of value in Table 1. The pooled value for mild drug-
related adverse events was calculated by combining the
results of values for mild gastrointestinal and mild sleep
related AEs. A pooled result for the value of being on no
prophylaxis was calculated by combining the value of
stopping chemoprophylaxis due to adverse events while
traveling with values for taking no prophylaxis despite
malaria risk. For the utility value estimates of mild drug-
related AE and being off prophylaxis, only the pooled
results were used, since those values would be required
for modeling purposes.
Survey of malaria experts
The 11 tropical medicine specialists estimated a mean
duration of hospitalization or equivalent disability for
simple malaria of 3.23 days (range 0.5-4.5 days). For
severe or complicated malaria the estimated mean length
of stay was 6.36 days (range 4.5 - 7 days). The utility esti-McCarthy and Coyle Malaria Journal 2010, 9:92
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Figure 1 Malaria Visual Analogue Scale: Risk and Outcomes of Malaria and Chemoprophylaxis.
 
I have just been discharged from 
hospital due to a severe case of 
malaria  
I can carry out all of my activities 
of daily living (no problems in 
walking about, no problems with 
self-care) 
I have some ongoing problems with 
concentrating at work 
I have a mild kidney problem as a 
result of the infection 
 
I am visiting a country where 
malaria occurs commonly 
I was taking my anti-malarial 
medication that is totally effective 
in more than 90% of cases 
I suffered a severe side effect of the 
medication, I had a seizure or 
epileptic fit. 
 
I am visiting a country where 
malaria occurs commonly 
I am taking my anti-malarial 
medication which totally effective 
in more than 90% of cases 
I have some difficulty with sleeping 
the night following my dose of anti-
malarial medication 
I am able to pursue work, family 
and leisure activities 
 
I am visiting a country where malaria 
occurs commonly 
I had to stop my anti-malarial 
medication  
I have no other anti-malarial 
medication available and will remain 
in Africa for another 3 weeks. 
Without my medication I have a 2% 




I am visiting a country where 
malaria occurs commonly 
I am taking my anti-malarial 
medication that is totally effective 
in more than 90% of cases, as 
prescribed   
I have no side effects from the 
medication 
I am visiting a country where 
malaria occurs commonly 
I am taking my anti-malarial 
medication that is totally 
effective in more than 90% of 
cases, as prescribed 
I have a mild upset stomach for 
30 minutes after each dose of 
medication 
I am able to pursue all work, 
family and leisure activities 
I am dead 
 
I am visiting a country where 
malaria occurs commonly 
I decided before travel that I would 
not take any medication to prevent 
malaria. 
I have a 2% (1 in 50) chance of 
contracting malaria. 
1 
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mates calculated from the questionnaire results are pre-
sented in Table 1.
Discussion and Conclusions
The results from members of the general public, who rep-
resent potential travellers, suggests that they are more
tolerant of taking prophylaxis whether associated with no
o r  m i l d  A E s .  T h e y  a r e  l e a s t  t o l e r a n t  o f  m i l d  m a l a r i a
sequelae and severe drug- related AEs. The rating value
reported for being off prophylaxis was quite variable.
This may in part reflect the scenario presented to partici-
pants related to malaria risk and efficacy of chemopro-
phylaxis communicated in the VAS research tool. An
individual traveller who is unaware or unconcerned about
malaria risk related to their travel may provide different
results. Therefore, one limitation of this tool may be the
participants' perceived malaria risk (our scenario
included the risk for travel to West Africa), the results
may vary with lower areas of risk. The survey respon-
dents were not a random sample, which may limit the
generalizability of the results obtained. However, these
estimates are still the best available estimates in the litera-
ture with respect to utility values for malaria and malaria
chemoprophylaxis related health states. The excess repre-
sentation of women (70%) may also impact our results. As
well, the authors recognize that the tolerance of malaria
and drug-related outcomes may change in different trav-
eling populations. In future the methods adopted in this
study can be used in different populations with varying
malaria risk and tolerance, to ensure generalizability.
Table 1: Survey Results and Utility Estimates c
General Public/Potential Travellers (N = 20)
Survey Results Utility Values
VAS Scenario Mean Standard Error Mean Standard Error
On Drug No AE 0.9725 0.0064 0.9993 0.0003




Mild Sleep AE 0.8180 0.0186
Pooled Off Drug 0.5368 0.0400 0.7541 0.0430
Stopped drug 0.5325 0.0547
No drug 0.5410 0.0597
Mild Malaria Sequelae 
(RF)
0.3920 0.0448 0.6304 0.0583
Severe Drug Related 
AE
0.3165 0.0323 0.5363 0.0555
Malaria Experts (N = 11)
Survey Results (days) Utility Values
Mean Standard Error Mean Standard Error
Simple Malaria 3.23 0.2727 0.5390 0.0390
Severe Malaria 6.36 0.426 0.0910 0.0610McCarthy and Coyle Malaria Journal 2010, 9:92
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The estimated days of hospital stay for complicated and
non-complicated malaria provided by the clinical experts
are in keeping with previous case series and observational
studies of outcomes of imported travellers' malaria in
non-endemic countries. Those studies reported hospital
stays of 3-4 days (range 0-8) for simple and 5-9 days
(range 2-20) for severe PF malaria[16-19]. It is possible
that the experience of the experts used for the survey,
mainly from North America, may differ from providers in
other non-endemic areas.
In conclusion, this study provides a benchmark for
important utility value estimates for those modeling
malaria and drug-related outcomes in non-immune trav-
ellers. Further studies can be conducted using random
samples of the general public and a larger sample size, but
given the current lack of data, it could be suggested that
these estimates can be used when assessing the risk bene-
fit trade off associated with malaria chemoprophylaxis.
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